Cargando…

Gamma Knife Radiosurgery for Cushing’s Disease: Evaluation of Biological Effective Dose from a Single-Center Experience

Objective: Gamma knife radiosurgery (GKRS) has served as an adjunctive treatment in Cushing’s disease (CD) for decades and has become a vital part of therapy in the management of CD. Biological effective dose (BED) is a radiobiological parameter with time correction, considering the cellular deoxyri...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Yuan, Wang, Mengqi, Wu, Yang, Deng, Hao, Xu, Yangyang, Ren, Yan, Wang, Chun, Wang, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9966465/
https://www.ncbi.nlm.nih.gov/pubmed/36835822
http://dx.doi.org/10.3390/jcm12041288
_version_ 1784897023977193472
author Gao, Yuan
Wang, Mengqi
Wu, Yang
Deng, Hao
Xu, Yangyang
Ren, Yan
Wang, Chun
Wang, Wei
author_facet Gao, Yuan
Wang, Mengqi
Wu, Yang
Deng, Hao
Xu, Yangyang
Ren, Yan
Wang, Chun
Wang, Wei
author_sort Gao, Yuan
collection PubMed
description Objective: Gamma knife radiosurgery (GKRS) has served as an adjunctive treatment in Cushing’s disease (CD) for decades and has become a vital part of therapy in the management of CD. Biological effective dose (BED) is a radiobiological parameter with time correction, considering the cellular deoxyribonucleic acid repairment. We aimed to investigate the safety and efficacy of GKRS for CD and evaluate the association of BED and treatment outcome. Methods: A cohort study of 31 patients with CD received GKRS in West China Hospital between June 2010 and December 2021. Endocrine remission was defined as normalization of 24 h urinary free cortisol (UFC) or serum cortisol ≤ 50 nmol/L after a 1 mg dexamethasone suppression test. Result: The mean age was 38.6 years old, and females accounted for 77.4%. GKRS was the initial treatment for 21 patients (67.7%), and 32.3% of patients underwent GKRS after surgery due to residual disease and recurrence. The mean endocrine follow-up duration was 22 months. The median marginal dose was 28.0 Gy, and the median BED was 221.5 Gy(2.47). Fourteen patients (45.1%) experienced control of hypercortisolism in the absence of pharmacological treatment, and the median duration to remission was 20.0 months. The cumulative rates of endocrine remission at 1, 2, and 3 years after GKRS were 18.9%, 55.3%, and 72.21%, respectively. The total complication rate was 25.8%, and the mean duration from GKRS to hypopituitary was 17.5 months. The new hypopituitary rate at 1, 2, and 3 years were 7.1%, 30.3%, and 48.4%, respectively. A high BED level (BED > 205 Gy(2.47)) was associated with better endocrine remission than a low BED level (BED ≤ 205 Gy(2.47)), while no significant differences were found between the BED level and hypopituitarism. Conclusions: GKRS was a second-line therapeutic option for CD with satisfactory safety and efficacy. BED should be considered during GKRS treatment planning, and optimization of BED is a potentially impactful avenue toward improving the efficacy of GKRS.
format Online
Article
Text
id pubmed-9966465
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99664652023-02-26 Gamma Knife Radiosurgery for Cushing’s Disease: Evaluation of Biological Effective Dose from a Single-Center Experience Gao, Yuan Wang, Mengqi Wu, Yang Deng, Hao Xu, Yangyang Ren, Yan Wang, Chun Wang, Wei J Clin Med Article Objective: Gamma knife radiosurgery (GKRS) has served as an adjunctive treatment in Cushing’s disease (CD) for decades and has become a vital part of therapy in the management of CD. Biological effective dose (BED) is a radiobiological parameter with time correction, considering the cellular deoxyribonucleic acid repairment. We aimed to investigate the safety and efficacy of GKRS for CD and evaluate the association of BED and treatment outcome. Methods: A cohort study of 31 patients with CD received GKRS in West China Hospital between June 2010 and December 2021. Endocrine remission was defined as normalization of 24 h urinary free cortisol (UFC) or serum cortisol ≤ 50 nmol/L after a 1 mg dexamethasone suppression test. Result: The mean age was 38.6 years old, and females accounted for 77.4%. GKRS was the initial treatment for 21 patients (67.7%), and 32.3% of patients underwent GKRS after surgery due to residual disease and recurrence. The mean endocrine follow-up duration was 22 months. The median marginal dose was 28.0 Gy, and the median BED was 221.5 Gy(2.47). Fourteen patients (45.1%) experienced control of hypercortisolism in the absence of pharmacological treatment, and the median duration to remission was 20.0 months. The cumulative rates of endocrine remission at 1, 2, and 3 years after GKRS were 18.9%, 55.3%, and 72.21%, respectively. The total complication rate was 25.8%, and the mean duration from GKRS to hypopituitary was 17.5 months. The new hypopituitary rate at 1, 2, and 3 years were 7.1%, 30.3%, and 48.4%, respectively. A high BED level (BED > 205 Gy(2.47)) was associated with better endocrine remission than a low BED level (BED ≤ 205 Gy(2.47)), while no significant differences were found between the BED level and hypopituitarism. Conclusions: GKRS was a second-line therapeutic option for CD with satisfactory safety and efficacy. BED should be considered during GKRS treatment planning, and optimization of BED is a potentially impactful avenue toward improving the efficacy of GKRS. MDPI 2023-02-06 /pmc/articles/PMC9966465/ /pubmed/36835822 http://dx.doi.org/10.3390/jcm12041288 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Gao, Yuan
Wang, Mengqi
Wu, Yang
Deng, Hao
Xu, Yangyang
Ren, Yan
Wang, Chun
Wang, Wei
Gamma Knife Radiosurgery for Cushing’s Disease: Evaluation of Biological Effective Dose from a Single-Center Experience
title Gamma Knife Radiosurgery for Cushing’s Disease: Evaluation of Biological Effective Dose from a Single-Center Experience
title_full Gamma Knife Radiosurgery for Cushing’s Disease: Evaluation of Biological Effective Dose from a Single-Center Experience
title_fullStr Gamma Knife Radiosurgery for Cushing’s Disease: Evaluation of Biological Effective Dose from a Single-Center Experience
title_full_unstemmed Gamma Knife Radiosurgery for Cushing’s Disease: Evaluation of Biological Effective Dose from a Single-Center Experience
title_short Gamma Knife Radiosurgery for Cushing’s Disease: Evaluation of Biological Effective Dose from a Single-Center Experience
title_sort gamma knife radiosurgery for cushing’s disease: evaluation of biological effective dose from a single-center experience
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9966465/
https://www.ncbi.nlm.nih.gov/pubmed/36835822
http://dx.doi.org/10.3390/jcm12041288
work_keys_str_mv AT gaoyuan gammakniferadiosurgeryforcushingsdiseaseevaluationofbiologicaleffectivedosefromasinglecenterexperience
AT wangmengqi gammakniferadiosurgeryforcushingsdiseaseevaluationofbiologicaleffectivedosefromasinglecenterexperience
AT wuyang gammakniferadiosurgeryforcushingsdiseaseevaluationofbiologicaleffectivedosefromasinglecenterexperience
AT denghao gammakniferadiosurgeryforcushingsdiseaseevaluationofbiologicaleffectivedosefromasinglecenterexperience
AT xuyangyang gammakniferadiosurgeryforcushingsdiseaseevaluationofbiologicaleffectivedosefromasinglecenterexperience
AT renyan gammakniferadiosurgeryforcushingsdiseaseevaluationofbiologicaleffectivedosefromasinglecenterexperience
AT wangchun gammakniferadiosurgeryforcushingsdiseaseevaluationofbiologicaleffectivedosefromasinglecenterexperience
AT wangwei gammakniferadiosurgeryforcushingsdiseaseevaluationofbiologicaleffectivedosefromasinglecenterexperience